Screening and diagnosis

Explore NCCN Guidelines® for lung cancer screening in select high-risk patients, the benefits of early screening with low-dose CT, and prognosis by stage of disease.

RISK ASSESSMENT

Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend lung cancer screening in select High-Risk patients1

In 2011, approximately 94 million current or former smokers were considered to be at elevated risk for lung cancer.2

References:1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening v3.2017. © National Comprehensive Cancer Network, Inc 2016.All rights reserved. Accessed June 14, 2016. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. The National Lung Screening Trial Research Team. N Engl J Med. 2011;365(5):395-409.

SCREENING

Earlier Screening With Low-dose CT Reduces Mortality From Lung Cancer 1

The National Lung Cancer Screening Trial randomized 53,454 adults at high risk for lung cancer to compare mortality with annual screening of either low-dose CT or chest radiography.

From The New England Journal of Medicine, The National Lung Screening Trial Research Team, Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. Vol 365, Page 405. Copyright  © (2011) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.

  • More adenocarcinoma and squamous cell carcinoma were detected at an earlier stage (stage I) with low-dose CT (computed tomography) screening, compared with single-view posteroanterior chest x-ray screening1
  • Screening high-risk patients with low-dose CT represents a relative reduction in the risk of mortality from lung cancer by 20%1

Reference: 1. The National Lung Screening Trial Research Team. N Engl J Med. 2011;365(5):395-409.

PROGNOSIS BY STAGE

NSCLC5-Year Survival Decreases With Advanced Stage of Disease at Diagnosis1,b

 

Stage at diagnosis

  • Localized: confined to primary site
  • Regional: spread to regional lymph nodes
  • Distant: cancer has metastasized

aIncludes lung and bronchus.
bBased on registry data of cancer diagnosed 2005-2011, all races, both sexes.

Reference: 1. National Cancer Institute. SEER stat fact sheets: lung and  bronchus cancer. http://seer.cancer.gov/statfacts/html/lungb.html. Accessed March 31,2015.

Back to top
click me